Advertisement
Singapore markets close in 1 hour 14 minutes
  • Straits Times Index

    3,285.63
    -7.50 (-0.23%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,258.76
    +57.49 (+0.33%)
     
  • FTSE 100

    8,078.40
    +38.02 (+0.47%)
     
  • Bitcoin USD

    63,935.25
    -2,757.79 (-4.14%)
     
  • CMC Crypto 200

    1,389.43
    +6.85 (+0.50%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • Dow

    38,460.92
    -42.77 (-0.11%)
     
  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     
  • Gold

    2,334.20
    -4.20 (-0.18%)
     
  • Crude Oil

    82.93
    +0.12 (+0.14%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • FTSE Bursa Malaysia

    1,569.97
    -1.51 (-0.10%)
     
  • Jakarta Composite Index

    7,154.00
    -20.54 (-0.29%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Is Merck's Planned Acquisition of Acceleron in Trouble?

In September, Merck (NYSE: MRK) announced plans to acquire Acceleron Pharma (NASDAQ: XLRN) for $11.5 billion. In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Merck's move doesn't mean that the acquisition of Acceleron is in trouble.